Check out today’s featured companies who have recently raised a round of funding, and be sure to check out the full list of past healthcare IT fundings.
HPS/PayMedix Secures $33 Million Investment
New Growth Equity Investment, Led by HLM Investment Partners, Will Accelerate Growth of the PayMedix Financing Platform Nationally
HPS/PayMedix, the leading healthcare financing and payments solutions provider, today announced it has closed $33 million in equity and debt financing to accelerate the growth of its groundbreaking PayMedix healthcare financing and payments solution. HLM Investment Partners, a leading healthcare investment firm, led a $16 million growth equity investment, joined by Escalate Capital Partners and RVM Enterprises, and existing investor SV Health Investors.
The funding comes at a time of notable growth for the company, as demand increases for its innovative healthcare payments platform to improve affordable access to healthcare nationwide.
“PayMedix is a highly effective platform that streamlines the payment experience for payors, providers, and members,” said Michael Ludwig, Partner at HLM Investment Partners, who will join the HPS/PayMedix board of directors as part of the transaction. “In a time where it is critical to reduce provider abrasion and improve member affordability, we are excited to partner with Tom and the HPS/PayMedix team to accelerate growth.”
The new term debt facility of $17 million was provided by Escalate Capital Partners, a leading private credit and growth equity investment firm that services growing companies within the technology, software, services, and healthcare sectors.
“As employers, providers, and payors look for alternative financing and payment solutions to deal with the affordability crisis in healthcare, demand for PayMedix has skyrocketed in the last year,” said Tom Policelli, HPS/PayMedix CEO…
Full release here, originally announced January 13th, 2026.
RISA Labs Closes $11.1M Series A to Scale AI Operating System for Oncology Nationwide
RISA Labs, a company pioneering an AI operating system for oncology, today announced the closing of an $11.1 million Series A funding round. The financing was co-led by Cencora Ventures and Optum Ventures, with participation from Oncology Ventures, Z21 Ventures, and John Simon (Co-Founder of General Catalyst) via his Ventureforgood investment entity.
The funding will accelerate the deployment of RISA’s system to cancer clinics, health systems, specialty pharmacies, and infusion networks across the United States, changing how complex oncology workflows are managed end-to-end.
In oncology, delays are costly for all stakeholders: patients, practices, payers, and pharma. Addressing this, RISA orchestrates patient access, benefits verification, and prior authorization, turning manual bottlenecks into predictable, high-throughput workflows across the cancer service line. In just nine months, partner institutions have already expanded from initial deployment to second and third workflows, reflecting rapid adoption and operational trust.
“In our vision for oncology, there are two sides to every patient’s journey: getting them on the right therapy faster and deepening our understanding of the disease for the next patient through data,” said Kshitij Jaggi, CEO at RISA Labs.
RISA connects directly to a cancer center’s electronic medical record (EMR), payer and benefits systems, and other systems of record. A team of AI agents reads, reasons, and acts across these systems, gathering the right data, preparing and submitting authorizations, tracking status, and progressing cases across dozens of payer environments, EMRs, and other tools. As forms, rules, or interfaces change, the agents adapt in real time, so workflows stay reliable without constant reprogramming…
Full release here, originally announced January 13th, 2026.
No comments:
Post a Comment